UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Nature communications, 2019-05, Vol.10 (1), p.2087-12, Article 2087

2019

Volltextzugriff (PDF)

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

Nature (London), 2022-04, Vol.604 (7906), p.563-570

2022

Volltextzugriff (PDF)

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas

Blood, 2018-10, Vol.132 (14), p.1495-1506

2018

Volltextzugriff (PDF)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Nature communications, 2023-11, Vol.14 (1), p.7509-7509, Article 7509

2023

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19

Clinical cancer research, 2019-12, Vol.25 (23), p.7046-7057

2019

Volltextzugriff (PDF)

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies

Blood cancer discovery, 2022-03, Vol.3 (2), p.136-153

2022

Volltextzugriff (PDF)

Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing

Nature biotechnology, 2019-03, Vol.37 (3), p.276-282

2019

Volltextzugriff (PDF)

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Nature biotechnology, 2019-09, Vol.37 (9), p.1049-1058

2019

Volltextzugriff (PDF)

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

Science translational medicine, 2021-01, Vol.13 (575)

2021

Volltextzugriff (PDF)

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Journal for Immunotherapy of Cancer, 2017-03, Vol.5 (1), p.28-28, Article 28

2017

Volltextzugriff (PDF)

Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells

Cancer cell, 2020-02, Vol.37 (2), p.143-144

2020

Volltextzugriff (PDF)

323 Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A367-A367

2023

Volltextzugriff (PDF)

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

Cancer cell, 2022-05, Vol.40 (5), p.494-508.e5

2022

Volltextzugriff (PDF)

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Journal for immunotherapy of cancer, 2019-11, Vol.7 (1), p.304-8, Article 304

2019

Volltextzugriff (PDF)

221 CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A234-A234

2021

Volltextzugriff (PDF)

301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A344-A344

2023

Volltextzugriff (PDF)

767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A459-A459

2020

Volltextzugriff (PDF)

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Blood, 2016-01, Vol.127 (2), p.221-232

2016

Volltextzugriff (PDF)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma

Frontiers in oncology, 2019-04, Vol.9, p.259-259

2019

Volltextzugriff (PDF)

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

Blood advances, 2019-11, Vol.3 (21), p.3248-3260

2019

Volltextzugriff (PDF)

The RNA-binding protein ESRP1 promotes human colorectal cancer progression

Oncotarget, 2017-02, Vol.8 (6), p.10007-10024

2017

Volltextzugriff (PDF)

Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays

Advanced science, 2019-12, Vol.6 (23), p.1901829-n/a

2019

Volltextzugriff (PDF)

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Cell stem cell, 2022-08, Vol.29 (8), p.1181-1196.e6

2022

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies

Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells

323 Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

221 CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors

301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC

767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma

CAR-Based Approaches to Cutaneous T-Cell Lymphoma

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

The RNA-binding protein ESRP1 promotes human colorectal cancer progression

Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Suchergebnisse filtern